FDA Inspection 1132387 — Cayman Pharma s.r.o.

Cayman Pharma s.r.o. — FEI 3003625059

The FDA completed an inspection of Cayman Pharma s.r.o. on January 30, 2020 in Neratovice. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
January 30, 2020
Fiscal Year
2020
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Neratovice (Czech Republic)

Additional Details

Mutual Recognition Agreement (MRA)